OBJECTIVE: The purpose of this study was to investigate the longitudinal changes in quality of life (QoL) for patients with advanced stage (stage III or IV) head and neck squamous cell carcinoma (HNSCC) following primary radiotherapy (RT) or concomitant chemoradiotherapy. METHODS: From January 2001 to January 2003, 149 patients with advanced HNSCC were enrolled. The data pertaining to their QoL were collected using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and the EORTC Head and Neck Module (QLQ-H&N35) before and 1 year after RT. RESULTS: Sixty-eight (46%) patients dropped out during the study period. Thirty-nine (57%) of them died of cancer. Those who were older, stage IV, treated by RT alone, or had worse pretreatment EORTC QoL scales were significantly more likely to drop out. For those completing the study, only the problems of swallowing, dry mouth, and sticky saliva were found to become more serious with both statistical (p < 0.05) and clinical (difference >10 points) significance 1 year after RT. Those subjects with cancer at the hypopharynx/larynx had a 3.3-fold higher probability to report an improvement in global QoL (95% confidence interval, CI: 1.11-6.82) than those with cancer at the oral cavity/oropharynx. Those alive without cancer 1 year after RT had a 3.6-fold higher probability to report an improvement in global QoL (95% CI: 1.32-7.13) than those alive with cancer. CONCLUSION: The study showed a high dropout rate in this longitudinal QoL study for patients with advanced HNSCC. Pretreatment cancer sites and living with cancer or not after treatment significantly affected the change in global QoL 1 year after RT. (c) 2005 S. Karger AG, Basel
OBJECTIVE: The purpose of this study was to investigate the longitudinal changes in quality of life (QoL) for patients with advanced stage (stage III or IV) head and neck squamous cell carcinoma (HNSCC) following primary radiotherapy (RT) or concomitant chemoradiotherapy. METHODS: From January 2001 to January 2003, 149 patients with advanced HNSCC were enrolled. The data pertaining to their QoL were collected using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and the EORTC Head and Neck Module (QLQ-H&N35) before and 1 year after RT. RESULTS: Sixty-eight (46%) patients dropped out during the study period. Thirty-nine (57%) of them died of cancer. Those who were older, stage IV, treated by RT alone, or had worse pretreatment EORTC QoL scales were significantly more likely to drop out. For those completing the study, only the problems of swallowing, dry mouth, and sticky saliva were found to become more serious with both statistical (p < 0.05) and clinical (difference >10 points) significance 1 year after RT. Those subjects with cancer at the hypopharynx/larynx had a 3.3-fold higher probability to report an improvement in global QoL (95% confidence interval, CI: 1.11-6.82) than those with cancer at the oral cavity/oropharynx. Those alive without cancer 1 year after RT had a 3.6-fold higher probability to report an improvement in global QoL (95% CI: 1.32-7.13) than those alive with cancer. CONCLUSION: The study showed a high dropout rate in this longitudinal QoL study for patients with advanced HNSCC. Pretreatment cancer sites and living with cancer or not after treatment significantly affected the change in global QoL 1 year after RT. (c) 2005 S. Karger AG, Basel
Authors: Allan J Hovan; P Michele Williams; Peter Stevenson-Moore; Yula B Wahlin; Kirsten E O Ohrn; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-05-22 Impact factor: 3.603
Authors: Harriët Jager-Wittenaar; Pieter U Dijkstra; Arjan Vissink; Bernard F A M van der Laan; Rob P van Oort; Jan L N Roodenburg Journal: Support Care Cancer Date: 2007-02-03 Impact factor: 3.603
Authors: Canhua Xiao; Jonathan J Beitler; Kristin A Higgins; Karen Conneely; Bhakti Dwivedi; Jennifer Felger; Evanthia C Wommack; Dong M Shin; Nabil F Saba; Luke Yeeloo Ong; Jeanne Kowalski; Deborah W Bruner; Andrew H Miller Journal: Brain Behav Immun Date: 2015-10-30 Impact factor: 7.217
Authors: Sourabha K Patro; Naresh K Panda; Jaimanti Bakshi; Roshan K Verma; Parmod Kumar; Sunil Gaba; Jerry R John Journal: Indian J Otolaryngol Head Neck Surg Date: 2018-02-22
Authors: Joel B Epstein; Catherine Hong; Richard M Logan; Andrei Barasch; Sharon M Gordon; Loree Oberle-Edwards; Lorree Oberlee-Edwards; Deborah McGuire; Joel J Napenas; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-06-11 Impact factor: 3.603
Authors: S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan Journal: Support Care Cancer Date: 2010-03-17 Impact factor: 3.603
Authors: Lisette van der Molen; Maya A van Rossum; Lori M Burkhead; Ludi E Smeele; Frans J M Hilgers Journal: Eur Arch Otorhinolaryngol Date: 2008-09-30 Impact factor: 2.503
Authors: C M L van Herpen; M E Mauer; R Mesia; M Degardin; S Jelic; C Coens; J Betka; J Bernier; E Remenar; J S Stewart; J H Preiss; D van den Weyngaert; A Bottomley; J B Vermorken Journal: Br J Cancer Date: 2010-09-14 Impact factor: 7.640